<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626184</url>
  </required_header>
  <id_info>
    <org_study_id>ALV003-0811</org_study_id>
    <nct_id>NCT00626184</nct_id>
  </id_info>
  <brief_title>A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease</brief_title>
  <official_title>A Phase 1, Two Stage, Single Dose, Single-Blind, Placebo Controlled, Dose Escalation, Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvine Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvine Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety and tolerability of ALV003 in healthy volunteers and patients with Celiac
      Disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Two Stage, Single Dose, Single-Blind, Placebo Controlled, Dose Escalation,
      Crossover Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and
      Subjects With Well-Controlled Celiac Disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>Throughout</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active study Drug: ALV003</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 dose levels of ALV003</intervention_name>
    <description>4 dose levels of ALV003 vs placebo</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>ALV003 and ALV003 placebo equivalent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION

          -  Health Status

               1. Healthy volunteers must be in good health

               2. Celiac Disease must be well controlled and in good health

          -  Either male or non-lactating, non-pregnant females who are postmenopausal, sterile or
             using at least two acceptable and highly effective birth control methods.

          -  Body Mass Index (BMI) of &lt; 30 kg/m2,

        EXCLUSION

          -  A positive urine test for alcohol or illegal drugs at screening.

          -  The subject has received an experimental drug within 30 days of the present study.

          -  History of substance abuse, within the last 5 years

          -  Clinically significant abnormal lab values, as determined by the PI

          -  Alcohol consumption of &gt; 2 standard drinks equivalents per day12. Positive pregnancy
             test within 7 days prior to study drug administration.

          -  history of any medically significant condition considered by the PI to adversely
             affect participation in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijaya Pratha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Applications Laboratory Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Applications Laboratories Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://alvinepharma.com</url>
    <description>Alvine Home page</description>
  </link>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>August 17, 2009</last_update_submitted>
  <last_update_submitted_qc>August 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vijaya Pratha, M.D., Principal Investigator</name_title>
    <organization>Clinical Applications Laboratories Inc.</organization>
  </responsible_party>
  <keyword>Celiac Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

